http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003224464-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78587acbfc8d4c9e9ac3baa7021087d7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4703 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2003-01-31^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c65febd5aba76463fd6135d0c46ab972 |
| publicationDate | 2003-12-04^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003224464-A1 |
| titleOfInvention | Secreted caveolin as a marker for prostate cancer |
| abstract | Prostate cancer cells secrete cav-1 and that secreted cav-1 can stimulate viability and clonal growth in prostate cancer cells that do not express cav-1. The concept of a secreted autocrine or paracrine factor that directly contributes to androgen resistance in prostate cancer is novel and represents an efficient mechanism for maximizing resistance to various pro-apoptotic stimuli that metastatic cells often encounter during the highly inefficient process of metastasis. The detection of secreted cav-1 in patient sera has significant potential for clinical utility. Since, unlike PSA, secreted cav-1 is linked to malignant characteristics of prostate cancer cells, serum cav-1 has a unique prognostic and diagnostic capacity. The levels of cav-1 protein within prostate cancer tissues were evaluated directly using immunohistochemistry and RT-PCR as well as serum cav-1 levels in men who undergo radical prostatectomy with lymph node dissection. This identified prostate cancer related cav-1 as a bio-marker with unique clinical potential including independent value in predicting biochemical recurrence following radical prostatectomy and prognostic significance. Cav-1 can also provide clinically useful prognostic information prior to surgery (biopsy and serum cav-1), is useful as a prognostic bio-marker, and also for the ability to predict the recurrence of prostate cancer. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013149058-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014037647-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9109961-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005202407-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010130527-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9494602-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10262103-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013036610-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9568483-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9458465-B2 |
| priorityDate | 2002-01-31^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 261 of 261.